Peel Hunt reaffirmed their buy rating on shares of Silence Therapeutics (LON:SLN) in a research note issued to investors on Friday, ThisIsMoney.Co.Uk reports.

Shares of LON:SLN opened at GBX 143 ($1.87) on Friday. Silence Therapeutics has a twelve month low of GBX 40 ($0.52) and a twelve month high of GBX 175 ($2.29). The stock’s 50 day moving average price is GBX 68.14. The firm has a market capitalization of $103.28 million and a price-to-earnings ratio of -5.46.

About Silence Therapeutics

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Featured Story: Futures Contract

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.